CALIBRATE: Interim Week 28 Results of Long-acting Subcutaneous Lenacapavir in Treatment-Naive Patients

July 18-21, 2021; Virtual
After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: July 24, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Rapid ART in adolescents leads to virologic suppression and upholds equity

Jason Halperin, MD, MPH Released: September 10, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Medication treatment for OUD improves HIV viral suppression rates

Jason Halperin, MD, MPH Released: September 10, 2021

Downloadable CCO slides from Rajesh T. Gandhi, MD, on evolving options for first-line ART and switching ART in patients with viral suppression

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD
Released: September 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue